Cipla Limited — Terbinafine Exporter Profile
Indian Pharmaceutical Exporter · #5 for Terbinafine · $1.3M export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Terbinafine with $1.3M in export value and 52 verified shipments. Cipla Limited holds a 4.9% market share in Terbinafine exports across 7 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Terbinafine Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Terbinafine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NEW ZEALAND | $407.3K | 26 | 45.8% |
| MAURITIUS | $140.5K | 10 | 15.8% |
| SOUTH AFRICA | $122.6K | 3 | 13.8% |
| CANADA | $100.0K | 2 | 11.2% |
| HONG KONG | $50.0K | 1 | 5.6% |
| TANZANIA | $48.3K | 2 | 5.4% |
| KENYA | $20.6K | 8 | 2.3% |
Cipla Limited exports Terbinafine to 7 countries. The largest destination is NEW ZEALAND accounting for 45.8% of Cipla Limited's Terbinafine shipments, followed by MAURITIUS (15.8%) and SOUTH AFRICA (13.8%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Terbinafine from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| REX MEDICAL LTD, | NEW ZEALAND | $241.5K | 17 |
| REX MEDICAL LTD | NEW ZEALAND | $165.8K | 9 |
| IBL LTD (HEALTHACTIV) | MAURITIUS | $119.0K | 9 |
| PHARMASCIENCE INC | CANADA | $100.0K | 2 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $72.6K | 2 |
| CONTROLLED MEDICATIONS LIMITED | HONG KONG | $50.0K | 1 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $50.0K | 1 |
| JD PHARMACY | TANZANIA | $48.3K | 2 |
| IBL LTD | MAURITIUS | $21.5K | 1 |
| CIPLA KENYA LIMITED | KENYA | $10.1K | 2 |
Cipla Limited supplies Terbinafine to 13 buyers globally. The largest buyer is REX MEDICAL LTD, (NEW ZEALAND), followed by REX MEDICAL LTD (NEW ZEALAND) and IBL LTD (HEALTHACTIV) (MAURITIUS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Terbinafine Export Value and How Much Does Cipla Limited Contribute?
India exported $22.3M worth of Terbinafine through 3,118 shipments from 292 suppliers to 121 countries, serving 589 buyers globally. Cipla Limited contributes $1.3M to this total, accounting for 4.9% of India's Terbinafine exports. Cipla Limited ships Terbinafine to 7 countries through 13 buyers.
What Is the Average Shipment Value for Cipla Limited's Terbinafine Exports?
Cipla Limited's average Terbinafine shipment value is $25.8K per consignment, based on 52 shipments totaling $1.3M. The largest destination is NEW ZEALAND (45.8% of Cipla Limited's Terbinafine exports).
How Does Cipla Limited Compare to Other Indian Terbinafine Exporters?
Cipla Limited ranks #5 among 292 Indian Terbinafine exporters with a 4.9% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($10.2M), AUROBINDO PHARMA LIMITED ($2.4M), MANKIND PHARMA LIMITED ($2.0M). Cipla Limited processed 52 shipments to 7 destination countries.
What Terbinafine Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TERBIFIN 250 TABLET (TERBINAFINE HYDROCH | $64.3K | 5 |
| TERBINAFINE HYDROCHLORIDE 250MG TABLET(1 | $50.0K | 1 |
| TERBIFIN - 250mg TAB (TERBINAFINE HYDROC | $50.0K | 1 |
| LAMISPOR 250MG TABLETS TERBINAFINE HYDROCHLORIDE [25308PACKSX1X14'S] | $50.0K | 1 |
| TERBINAFINE HYDROCHLORIDE 250 MG TABLETINV.QTY.98.434 PACK 1X10000S=984340 NOS | $50.0K | 1 |
| LAMISPOR 250MG TABLETS (TERBINAFINE HYDROCHLORIDE) [30432(PACKS)X1X14'S] | $50.0K | 1 |
| DEOLATE TERBINAFINE 250 MG TABLET INV QTY 5115 PACK 6X14S 429660 NOS | $43.1K | 2 |
| DEOLATE (TERBINAFINE) 250 MG TABLET (INV.QTY. 5054 PACK 6X14'S=424536 NOS) | $42.4K | 2 |
| DEOLATE (TERBINAFINE) 250 MG TABLET (INV NO.5040 PACK 6 X 14'S = 423360 NOS) | $42.2K | 2 |
| DEOLATE TERBINAFINE 250 MG TABLET INV QTY 4988 PACK 6X14S 418992 NOS | $42.0K | 2 |
Cipla Limited exports 33 distinct Terbinafine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TERBIFIN 250 TABLET (TERBINAFINE HYDROCH with 5 shipments worth $64.3K.
Regulatory Requirements: Exporting Terbinafine to Key Markets
What Cipla Limited must comply with to export Terbinafine to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Terbinafine Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | AUROBINDO PHARMA LIMITED | $2.4M | 50 | 8 | $48.9K |
| 4 | MANKIND PHARMA LIMITED | $2.0M | 111 | 10 | $17.8K |
| 5 | CIPLA LIMITED ★ | $1.3M | 52 | 7 | $25.8K |
| 6 | IND SWIFT LIMITED | $1.2M | 40 | 7 | $28.8K |
| 7 | ORBION PHARMACEUTICALS PRIVATE LIMITED | $1.1M | 46 | 1 | $24.5K |
Cipla Limited ranks #5 among 292 Indian Terbinafine exporters. Average shipment value of $25.8K compared to the market average of $76.4K. The closest competitors by value are AUROBINDO PHARMA LIMITED and MANKIND PHARMA LIMITED.
Which Indian Ports Ship Terbinafine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 437 | 14.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 396 | 12.7% |
| DELHI AIR CARGO ACC (INDEL4) | 354 | 11.4% |
| DELHI AIR | 275 | 8.8% |
| NHAVA SHEVA SEA (INNSA1) | 233 | 7.5% |
| HYDERABAD ICD (INSNF6) | 111 | 3.6% |
| JNPT/ NHAVA SHEVA SEA | 106 | 3.4% |
| Bombay Air | 89 | 2.9% |
Geopolitical & Trade Policy Impact on Cipla Limited's Terbinafine Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Terbinafine, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Terbinafine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Terbinafine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 52 individual customs records matching Cipla Limited exporting Terbinafine, covering 33 formulations to 7 countries via 13 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 121+ countries, 589+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Terbinafine Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Terbinafine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Terbinafine Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Terbinafine. For current shipment-level data, contact TransData Nexus.